Maa: Australia
Kieli: englanti
Lähde: Department of Health (Therapeutic Goods Administration)
Epoetin alfa, Quantity: 40000 IU/mL
Janssen-Cilag Pty Ltd
Epoetin alfa
Injection, solution
Excipient Ingredients: glycine; polysorbate 80; monobasic sodium phosphate; water for injections; dibasic sodium phosphate dihydrate; sodium chloride
Intravenous, Subcutaneous
6 x 0.75mL
(S4) Prescription Only Medicine
Eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. Eprex is also indicated for the prevention and treatment of anaemia in adult patients with non-myeloid malignancies, where anaemia is anticipated to develop and develops as a result of concomitantly administered chemotherapy. Eprex is indicated to decrease the need for transfusion in patients who will continue to receive concomitant chemotherapy for a minimum of two months. Eprex is also indicated in adult patients with mild-to-moderate anaemia (haemoglobin >10 <=13 g/dL) scheduled for elective surgery with an expected moderate blood loss (2-4 units to 900 to 1800mL) to reduce exposure to allogenic blood transfusion and to facilitate erythropoietic recovery. EPREX is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adults patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.
Visual Identification: Clear, colourless solution, virtually free from foreign particulates.; Container Type: Syringe; Container Material: Glass Type I Clear; Container Life Time: 18 Months; Container Temperature: Store at 2 to 8 degrees Celsius
Registered
2008-01-14
EPREX ® PREFILLED SYRINGE 1 EPREX ® PREFILLED SYRINGES _(Epoetin alfa (rch)) _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about EPREX prefilled syringes. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. CURRENT AND UPDATED INFORMATION ABOUT BENEFITS AND SIDE EFFECTS OF EPREX IS CONTAINED IN THIS LEAFLET. Your doctor has weighed the risks of you using EPREX against the benefits this medicine is expected to have for you. If you have any concerns about using EPREX ask your doctor or pharmacist. IT IS IMPORTANT THAT YOU READ THIS LEAFLET. Keep this leaflet with your medicine. WHAT EPREX IS USED FOR EPREX prefilled syringes contain the active ingredient epoetin alfa, a protein that stimulates bone marrow to produce more red blood cells. Red blood cells are responsible for carrying oxygen to all parts of your body. A decrease in the number of red blood cells can cause anaemia. Some symptoms of anaemia are tiredness, breathlessness when exercising, and feeling cold. Anaemia may have many causes, including decreased production of a hormone called erythropoietin by the kidneys due to kidney failure, or as a result of chemotherapy treatments for cancer. EPREX is virtually identical to your body's erythropoietin, and has a similar effect to naturally occurring erythropoietin in your body. EPREX is used to treat the anaemia associated with kidney disease. If you have kidney disease, your kidney may not produce enough erythropoietin (necessary for red blood cell production) and your doctor may wish to correct this by prescribing EPREX. This medicine stimulates your bone marrow to produce more red blood cells, helping to treat your anaemia. EPREX can also be used to treat anaemia if you are receiving chemotherapy for cancer and your doctor decides that a blood transfusion is not appropriate. Doctors can also prescribe EPREX for mildly anaemic patients who are going Lue koko asiakirja
CCDS(201216v11) 1 EPREX(210701)API AUSTRALIAN PRODUCT INFORMATION EPREX ® EPOETIN ALFA (RCH) INTRAVENOUS & SUBCUTANEOUS INJECTION USE IN CANCER In some studies, use of Erythropoiesis Stimulating Agents (ESAs) to treat anaemia in patients with cancer has been associated with increased mortality. ESAs should only be used to treat anaemia that has developed as a result of concomitantly administered chemotherapy, and only when blood transfusion is not considered appropriate. Haemoglobin levels should not exceed 120g/L (see section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE). 1. NAME OF THE MEDICINE Epoetin alfa (rch) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION EPREX epoetin alfa (rch) 1,000 IU/0.5 mL injection syringe EPREX epoetin alfa (rch) 2,000 IU/0.5 mL injection syringe EPREX epoetin alfa (rch) 3,000 IU/0.3 mL injection syringe EPREX epoetin alfa (rch) 4,000 IU/0.4 mL injection syringe EPREX epoetin alfa (rch) 5,000 IU/0.5 mL injection syringe EPREX epoetin alfa (rch) 6,000 IU/0.6 mL injection syringe EPREX epoetin alfa (rch) 8,000 IU/0.8 mL injection syringe EPREX epoetin alfa (rch) 10,000 IU/1.0 mL injection syringe EPREX epoetin alfa (rch) 20,000 IU/0.5 mL injection syringe EPREX epoetin alfa (rch) 30,000 IU/0.75 mL injection syringe EPREX epoetin alfa (rch) 40,000 IU/1.0 mL injection syringe Epoetin alfa is recombinant human erythropoietin (EPO). It is expressed in Chinese hamster ovary cells (rch) and has a 165 amino acid sequence identical to that of human urinary EPO; the two are indistinguishable on the basis of functional assays. The apparent molecular weight of erythropoietin is about 30,400 daltons. EPREX ® is a sterile preservative-free phosphate buffered protein solution of Epoetin alfa (rch) in pre-filled syringes of 1,000 IU in 0.5 mL, 2,000 IU in 0.5 mL, 3,000 IU in 0.3 mL, 4,000 IU in 0.4 mL, 5000 IU in 0.5 mL, 6000 IU in 0.6 mL, 8000 IU in 0.8 mL, 10,000 IU in 1.0 mL, 20,000 IU in 0.5 mL, 30,000 IU in 0.75 mL and 40,000 IU (336 micrograms) in 1 mL. The formulation is stabilised with glycin Lue koko asiakirja